Business
Zhongchao Inc. Announces Its Patient Management System Improves Its Liver Cancer Patients' Duration of Therapy by 40%, Promoting Successful Treatment
SHANGHAI, Oct. 29, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare
About this update from Zhongchao Inc.
[{"type":"text","content":" SHANGHAI, Oct. 29, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) (\"Zhongchao\" or the \"Company\"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management platform, today announced its self-developed patient management system improves Duration of Therapy (\"DOT\") by 40.4% for liver cancer patients, which contributes to the maximum efficiency of drugs, successful treatment and longer patient survival terms. \nBy utilizing its self-developed patient management system, Zhongchao provides patients with coherent treatment process management through education, phone call follow-up, utility of intelligent tools to assist patients to control possible adverse reactions during treatment, psychological counseling, drugs usages reminder, treatment-related questions answering, and patients supervision to ensure that patients follow instructions as prescribed. For nearly 20,000 liver cancer patient users of the Company's patient management system, 180,000 medication usage records showed that compared to the DOT in clinical study, the DOT of the users improved 40.4% as a result of the improved treatment adherence. Meanwhile, according to the research article published by BMJ, good adherence was associated with lower mortality, and the mortality risks could reduce by 44% for patients with good adherence.\nAccording to The Global Cancer Observatory, there were around 400,000 new liver cancer cases in 2020 in China. Currently, the treatment of liver cancer mainly relies on surgical resection, interventional therapy, radiotherapy and liver transplantation while all treatment methods have certain limitations, however, combining with systemic therapies such as targeted drugs can improve the treatments effect. However, during the systemic therapies, one or several adverse reactions often lower patients' life quality and hinder their mental health, increasing difficulties in treatment and causing negative impact on patients' survival terms. As such, during the treatment, Zhongchao, through its patient management system, closely monitors and deals with the adverse reactions and focuses on managing follow-up visits to improve patients physical and mental conditions. The Company will continue to invest in its pa...